Robinson Smith Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Robinson Smith Wealth Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-390	Closed	-$219K	–	90
2025 Q3	$219K	Hold	390	–	–	0.16%	81
2025 Q2	$205K	Sell	390 -358	-48%	-$200K	0.16%	88
2025 Q1	$474K	Buy	748 +212	+40%	+$146K	0.4%	50
2024 Q4	$382K	Sell	536 -44	-8%	-$36.9K	0.32%	54
2024 Q3	$610K	Sell	580 -222	-28%	-$247K	0.52%	44
2024 Q2	$843K	Hold	802	–	–	0.74%	34
2024 Q1	$772K	Buy	802 +1	+0.1%	+$951	0.74%	38
2023 Q4	$704K	Buy	+801	New	+$660K	0.69%	37

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Robinson Smith Wealth Advisors's REGN Position: Q4 2025 in Review

Robinson Smith Wealth Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 390 shares — an estimated $219K sold.

Robinson Smith Wealth Advisors first reported a position in REGN in Q4 2023 and held it in 8 quarters. The position peaked at $843K in Q2 2024. 1,388 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

Robinson Smith Wealth Advisors reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Robinson Smith Wealth Advisors sold 390 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $219K.
Robinson Smith Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2023 and held it in 8 quarters.
Robinson Smith Wealth Advisors's Regeneron Pharmaceuticals position peaked at $843K in Q2 2024.
1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Robinson Smith Wealth Advisors's 13F filing for Q4 2025, filed 9 Feb 2026.